All In Biotech

Drug Trial Radar · NCT03768063

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Feb 28, 2019

Primary completion

Jul 5, 2028

Study completion Jul 5, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.

Conditions

  • Cancer

Interventions

  • AtezolizumabDrug

    Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).

  • BevacizumabDrug

    Bevacizumab will be administered as directed per the parent study.

  • AlectinibDrug

    Alectinib will be administered as directed per the parent study.

  • CobimetinibDrug

    Cobimetinib will be administered as directed per the parent study.

  • VemurafenibDrug

    Vemurafenib will be administered as directed per the parent study.

  • FAP IL2VDrug

    FAP IL2V will be administered as directed per the parent study.

  • VenetoclaxDrug

    Venetoclax will be administered as directed per the parent study.

  • EnzalutamideDrug

    Enzalutamide will be administered as directed per the parent study.

  • PembrolizumabDrug

    Pembrolizumab will be administered as directed per the parent study.

  • SunitinibDrug

    Sunitinib will be administered as directed per the parent study.

  • NiraparibDrug

    Niraparib will be administered as directed per the parent study.

  • CabozantinibDrug

    Cabozantinib will be administered as directed per the parent study.

  • PemetrexedDrug

    Pemetrexed will be administered as directed per the parent study.

  • PaclitaxelDrug

    Paclitaxel will be administered as directed per the parent study.

  • EmactuzumabDrug

    Emactuzumab will be administered as directed per the parent study.

  • RucaparibDrug

    Rucaparib will be administered as directed per the parent study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s)Time frame: Day 1 up to maximum 10 years

Locations

80 sites in 24 countries. Site status is shown where the registry gives one.

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Yale University School Of Medicine

    Trumbull, Connecticut

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Carolina BioOncology Institute, PLCC

    Huntersville, North Carolina

  • St. Luke's Cancer Care Associates

    Bethlehem, Pennsylvania

  • University of Texas Health Sciences Center in San Antonio

    San Antonio, Texas

  • St Vincent'S Hospital

    Darlinghurst, New South Wales, Australia

  • Institut Jules Bordet

    Brussels, Belgium

  • UZ Brussel

    Brussels, Belgium

  • UZ Leuven

    Leuven, Flemish Brabant, Belgium

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Multiprofile Hospital for Active Treatment Central Onco Hospital OOD

    Plovdiv, Bulgaria

  • Pontificia Universidad Catolica de Chile

    Santiago, Chile

  • Masaryk?v onkologický ústav

    Brno, Czechia

  • Rigshospitalet

    København Ø, Denmark

  • Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez

    Lille, France

  • hopital de la Timone

    Marseille, France

  • Institut Gustave Roussy

    Villejuif, Île-de-France Region, France

  • CHU Angers

    Angers, Pays de la Loire Region, France

  • Centre Antoine Lacassagne

    Nice, Provence-Alpes-Côte d'Azur Region, France

  • Kliniken Essen-Mitte

    Essen, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Asklepios-Fachklinik Muenchen-Gauting

    Gauting, Germany

  • SRH Wald-Klinikum Gera

    Gera, Germany

  • Lungenfachklinik Immenhausen

    Immenhausen, Germany

  • Universitaetsklinikum Muenster

    Münster, Germany

  • Universitaets-Hautklinik Tuebingen

    Tübingen, Germany

  • Universitaettsklinikum Tübingen

    Tübingen, Germany

  • Universitätsklinik Tübingen

    Tübingen, Germany

  • Universitätsklinikum Ulm

    Ulm, Baden-Wurttemberg, Germany

  • Krankenhaus Barmherzige Bruder Regensburg

    Regensburg, Bavaria, Germany

  • Universitätsklinikum Schleswig-Holstein;Campus Lübeck

    Lübeck, Schleswig-Holstein, Germany

  • Laiko General Hospital Athen

    Athens, Greece

  • Anticancer Hospital Ag. Savas

    Athens, Greece

  • Metropolitan Hospital

    Piraeus, Attica, Greece

  • Grupo Angeles

    Guatemala City, Guatemala

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Szegedi Tudományegyetem

    Szeged, Hungary

  • Istituto Nazionale dei Tumori

    Milan, Lombardy, Italy

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.